High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

AIMS: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. BACKGROUND: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its use is complicated by opportunistic JCV infectio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Adv Neurol Disord
Glavni autori: Dwyer, Christopher M., Jokubaitis, Vilija G., Stankovich, Jim, Baker, Josephine, Haartsen, Jodi, Butzkueven, Helmut, Cartwright, Adriana, Shuey, Neil, Fragoso, Yara Dadalti, Rath, Louise, Skibina, Olga, Fryer, Kylie, Butler, Ernest, Coleman, Jennifer, MacIntrye, Jennifer, Macdonell, Richard, van der Walt, Anneke
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2021
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053827/
https://ncbi.nlm.nih.gov/pubmed/33948117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286421998915
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items